Biography

Dr. Kekule Asgari

Medical Oncology

Sweden

22 years of experience

Specialty

Specialties:

Medical Oncology

Subspecialties:

Breast cancer

Procedures performed:

Work Experience

Staff Physician

City Kiniken

Norrtälje, Sweden.

from 2020

Oncology Physician

Kalmar Hospital

Kalmar, Sweden.

2016 - 2017

Physician

LäkarLeasing Medical Staffing

Stockholm, Sweden.

2013 - 2016

Consulting Physician

Dedicare Doctor AB

Stockholm, Sweden.

2013 - 2013

Oncologist

Private Oncology Clinic

Stockholm, Sweden.

2010 - 2011

Oncologist

Nastved Hospital

Nastved, Denmark.

2004 - 2011

Oncologist

Private Oncology Clinic

Houston, USA.

2008 - 2008

Research Assistant

Seattle and Saint Louis, USA.

2002 - 2004

Oncology Fellow

Johns Hopkins Oncology Center, Johns Hopkins Hospital

Baltimore, USA.

2000 - 2002

Research Fellow

The Center for Prostate Disease Research (CPDR), The Uniformed Services University of the Health Sciences, Department of Surgery and Medicine Branch of The National Cancer Institute

Bethesda, USA.

1994 - 1998

Student Researcher

Michigan Cancer Foundation

Detroit, USA.

1992 - 1992

Student Researcher

Clinical Genetic Institute, Copenhagen University Medical School

Copenhagen, Denmark.

1990 - 1990

Biography

Dr. Kekule Asgari did his oncology fellowship at the Johns Hopkins Hospital, USA. He has done various research activities in Seattle, WA, and Saint Louis, MO. As a research assistant there, he worked on two different projects: A: Local treatment options for liver metastasis. B: Role of DNA methylation in cancer pathology.

Dr. Asgari has medical experience in Sweden, Denmark, and the USA. He is a member of Swedish and Danish medical associations, the American society for basic research, and has medical licenses from Sweden & Denmark.

Education

Clinical Training, Department of General Internal Medicine, Johns Hopkins Outpatient Center

2000

MD, Copenhagen University Medical School

1994

Awards

No data found

Affiliations

Swedish Medical Association

Danish Medical Association

American Society for Basic Research

Publications

Evidence that GSTP-1 CpG island hyper methylation may be selected during human prostatic carcinogenesis

Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide

Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

Xenografts of human benign prostatic hyperplasia tissues in the nude mouse

Maintenance of human benign prostatic hyperplasia tissues in the nude mouse